Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4577513 | 0.90 | CA12 (0.53) | MEN1KMT2AALDH1A1GRIN1GRIN2B | |
| SCHEMBL4591294 | 0.90 | GRIN1 (0.51) | MEN1KMT2AALDH1A1GRIN2DGRIN3B | |
| SCHEMBL4591719 | 0.90 | MEN1 (0.55) | FAAHMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5803633 | 0.85 | SMN1; SMN2 (0.61) | FAAHMEN1KMT2AALDH1A1GRIN1 | |
| SCHEMBL4412638 | 0.83 | CHRNA7 (0.62) | FAAHCHRNA7GRIN2DGRIN3BGRIN1 | |
| SCHEMBL9444298 | 0.83 | POLB (0.51) | FAAHALDH1A1MAPT | |
| SCHEMBL4248473 | 0.81 | FAAH (0.52) | FAAHCHRNA7MEN1KMT2AALDH1A1 | |
| SCHEMBL4771631 | 0.76 | GPR119 (0.59) | — | |
| SCHEMBL5791545 | 0.76 | SMN1; SMN2 (0.60) | MEN1KMT2AALDH1A1GRIN1GRIN2B | |
| SCHEMBL4577310 | 0.76 | FAAH (0.68) | FAAHMEN1KMT2AALDH1A1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | FAAH 835/4885CHRNA7 104/4885MEN1 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.